Citations (11)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Leilei Ai, Jian Chen, Hao Yan, Qiaojun He, Peihua Luo, Zhifei Xu & Xiaochun Yang. (2020) Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy. Drug Design, Development and Therapy 14, pages 3625-3649.
Read now
Read now
Articles from other publishers (10)
Pankti C. Balar, Vasso Apostolopoulos & Vivek P. Chavda. (2024) A new era of immune therapeutics for pancreatic cancer: Monoclonal antibodies paving the way. European Journal of Pharmacology 969, pages 176451.
Crossref
Crossref
Simon Pernot, Mercedes Tomé, Isabel Galeano-Otero, Serge Evrard, Iker Badiola, Frederic Delom, Delphine Fessart, Tarik Smani, Geraldine Siegfried, Bruno O. Villoutreix & Abdel-Majid Khatib. (2024) Sulconazole inhibits PD-1 expression in immune cells and cancer cells malignant phenotype through NF-κB and calcium activity repression. Frontiers in Immunology 14.
Crossref
Crossref
家俊 刘. (2024) A Review of Immunotherapy in the Treatment of Tumors. Immunology Studies 06:01, pages 11-14.
Crossref
Crossref
Jocelyne Rivera, Antonia Digklia, Anna S. Christou, James Anibal, Katherine A. Vallis, Bradford J. Wood & Eleanor Stride. (2024) A Review of Ultrasound-Mediated Checkpoint Inhibitor Immunotherapy. Ultrasound in Medicine & Biology 50:1, pages 1-7.
Crossref
Crossref
Qingjing Wang, Xueting Shao, Yuxuan Zhang, Miaojin Zhu, Frederick X. C. Wang, Jianjian Mu, Jiaxuan Li, Hangping Yao & Keda Chen. (2023) Role of tumor microenvironment in cancer progression and therapeutic strategy. Cancer Medicine 12:10, pages 11149-11165.
Crossref
Crossref
Yavar Shiravand, Faezeh Khodadadi, Seyyed Mohammad Amin Kashani, Seyed Reza Hosseini-Fard, Shadi Hosseini, Habib Sadeghirad, Rahul Ladwa, Ken O’Byrne & Arutha Kulasinghe. (2022) Immune Checkpoint Inhibitors in Cancer Therapy. Current Oncology 29:5, pages 3044-3060.
Crossref
Crossref
Teruki Isobe, Taku Naiki, Yosuke Sugiyama, Aya Naiki-Ito, Takashi Nagai, Toshiki Etani, Satoshi Nozaki, Keitaro Iida, Yusuke Noda, Nobuhiko Shimizu, Nami Tomiyama, Rika Banno, Hiroki Kubota, Shuzo Hamamoto, Ryosuke Ando, Noriyasu Kawai & Takahiro Yasui. (2021) Chronological transition in outcome of second-line treatment in patients with metastatic urothelial cancer after pembrolizumab approval: a multicenter retrospective analysis. International Journal of Clinical Oncology 27:1, pages 165-174.
Crossref
Crossref
Adam S. Dayoub & Rolf A. Brekken. (2020) TIMs, TAMs, and PS- antibody targeting: implications for cancer immunotherapy. Cell Communication and Signaling 18:1.
Crossref
Crossref
Mohamad Moussa, Mohamed Abou Chakra, Baraa Dabboucy, Athanasios G Papatsoris & Youssef Fares. (2020) Seizure as the first manifestation of transitional cell carcinoma of the renal pelvis. Journal of Surgical Case Reports 2020:7.
Crossref
Crossref
Giulio Mandelli, Francesco Missale, Debora Bresciani, Luisa Benerini Gatta, Patrizia Scapini, Elena Caveggion, Elisa Roca, Mattia Bugatti, Matilde Monti, Luca Cristinelli, Sandra Belotti, Claudio Simeone, Stefano Calza, Laura Melocchi & William Vermi. (2020) Tumor Infiltrating Neutrophils Are Enriched in Basal-Type Urothelial Bladder Cancer. Cells 9:2, pages 291.
Crossref
Crossref